Lyra Therapeutics, Inc. (LYRA) is a clinical-stage biotechnology company developing anti-inflammatory therapies for chronic rhinosinusitis. While its core business activities are Shariah-compliant, the financial screening reveals significant non-compliance due to an exceptionally high interest income ratio of 192.44%, exceeding all standard thresholds. Debt and liquidity ratios are compliant, and no non-permissible business activities were identified. Index inclusion research confirms exclusion from all major Shariah indices. Overall, the company is classified as non-compliant, with a B quality rating reflecting strong business permissibility but critical financial concerns.